NASDAQ:GRCL
Gracell Biotechnologies Inc.
- Stock
Last Close
10.24
21/02 21:00
Market Cap
965.02M
Beta: −1.83
Volume Today
6.37M
Avg: 131.30K
PE Ratio
−12.25
PFCF: -
Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | ||
|---|---|---|---|---|---|---|
average inventory | 8.54M - | -10.79M 226.26% | -11.13M 3.19% | -8.82M 20.80% | ||
average payables | 31.23M - | 31.23M 0% | ||||
average receivables | 9.98M - | 22.37M 123.99% | 35.83M 60.18% | 33.51M 6.46% | ||
book value per share | 0.12 - | 12.89 10,615.74% | 12.50 3.02% | 27.78 122.23% | 13.12 52.79% | |
capex per share | -0.57 - | -2.85 396.89% | -1.21 57.49% | -0.86 28.76% | -0.46 46.53% | |
capex to depreciation | -3.80 - | -11.01 190.14% | -3.68 66.61% | -0.94 74.40% | -0.62 33.69% | |
capex to operating cash flow | 0.18 - | 0.42 127.01% | 0.40 3.86% | 0.19 53.50% | 0.10 46.19% | |
capex to revenue | -155.04 - | |||||
cash per share | 5.75 - | 15.97 177.69% | 11.79 26.15% | 27.86 136.31% | 13.90 50.11% | |
days of inventory on hand | ||||||
days payables outstanding | ||||||
days sales outstanding | 40.58K - | |||||
debt to assets | 0.93 - | 0.34 63.97% | 0.11 68.31% | 0.08 29.35% | 0.11 46.66% | |
debt to equity | 58.20 - | 0.54 99.07% | 0.13 76.89% | 0.08 32.35% | 0.13 56.62% | |
dividend yield | ||||||
earnings yield | -0.02 - | -0.04 114.67% | -0.02 51.87% | -0.18 900.27% | -0.37 98.37% | |
enterprise value | 3.54B - | 3.28B 7.24% | 10.06B 206.43% | 857.63M 91.48% | 392.38M 54.25% | |
enterprise value over ebitda | -61.26 - | -22.81 62.77% | -48.66 113.36% | -2.23 95.42% | -0.66 70.27% | |
ev to operating cash flow | -57.25 - | -24.26 57.62% | -50.79 109.38% | -2.82 94.46% | -0.81 71.13% | |
ev to sales | 2.34K - | |||||
free cash flow per share | -3.70 - | -9.68 162.01% | -4.23 56.28% | -5.49 29.76% | -5.06 7.84% | |
free cash flow yield | -0.02 - | -0.06 158.70% | -0.03 53.31% | -0.14 451.04% | -0.32 123.60% | |
graham net net | -1.20 - | 8.80 834.58% | 9.69 10.09% | 24.85 156.41% | 11.29 54.58% | |
graham number | 2.88 - | 43.99 1,426.37% | 29.08 33.89% | 66.54 128.79% | 41.34 37.87% | |
income quality | 1.02 - | 0.98 4.04% | 0.94 4.23% | 0.67 27.91% | 0.79 17.85% | |
intangibles to total assets | 0 - | 0 | 0 | 0 | 0 | |
interest coverage | -99.49 - | -91.56 7.97% | -92.72 1.27% | |||
interest debt per share | 7.00 - | 7.00 0% | 1.60 77.12% | 2.44 52.07% | 1.81 25.77% | |
inventory turnover | ||||||
invested capital | 58.20 - | 0.54 99.07% | 0.13 76.89% | 0.08 32.35% | 0.13 56.62% | |
market cap | 3.41B - | 3.46B 1.28% | 10.72B 209.90% | 2.53B 76.38% | 1.66B 34.27% | |
net current asset value | -18.17M - | 183.49M 1,109.70% | 670.18M 265.24% | 1.65B 146.55% | 1.22B 26.45% | |
net debt to ebitda | -2.19 - | 1.20 154.87% | 3.15 161.63% | 4.35 37.99% | 2.15 50.62% | |
net income per share | -3.07 - | -6.67 117.42% | -3.01 54.93% | -7.08 135.54% | -5.79 18.24% | |
operating cash flow per share | -3.12 - | -6.83 118.88% | -3.02 55.78% | -4.63 53.21% | -4.60 0.63% | |
payables turnover | ||||||
receivables turnover | 0.01 - | |||||
research and ddevelopement to revenue | 893.17 - | |||||
return on tangible assets | -0.41 - | -0.32 21.67% | -0.20 36.28% | -0.23 10.68% | -0.37 62.20% | |
revenue per share | 0.01 - | |||||
roe | -25.51 - | -0.52 97.97% | -0.24 53.53% | -0.25 5.99% | -0.44 73.21% | |
roic | -0.46 - | -0.35 22.16% | -0.22 39.02% | -0.24 9.73% | -0.39 66.34% | |
sales general and administrative to revenue | 374.43 - | |||||
shareholders equity per share | 0.12 - | 12.89 10,615.74% | 12.50 3.02% | 27.78 122.23% | 13.12 52.79% | |
stock based compensation to revenue | 164.98 - | |||||
tangible asset value | 2.38M - | 255.36M 10,615.74% | 819.66M 220.99% | 1.83B 122.94% | 1.38B 24.71% | |
tangible book value per share | 0.12 - | 12.89 10,615.74% | 12.50 3.02% | 27.78 122.23% | 13.12 52.79% | |
working capital | 120.52M - | 322.19M 167.33% | 722.11M 124.13% | 1.73B 139.57% | 1.28B 26.29% |
All numbers in USD (except ratios and percentages)